This cooperation with partners specialised in e.g. pharmaceuticals, diagnostics, medical devices, imaging or from the biotech and digital industries will help speed up the development and uptake of innovation in public health.
The partnership would build on the Innovative Medicines Initiative (IMI2), but would significantly revise its scope and expand its partners. This new partnership would strongly support the key strategic value chain on smart health, blending healthcare and digital technologies, digital media, mobile devices and biomedical engineering.